All News
A better way to fight cancer. Your molecular profile may reveal what treatments may be the most effective in your fight. #CarisCares #PrecisionMedicine #CancerCare
Caris Life Sciences carisls ( View Tweet)
#EULAR2021 Pres6882 @Rheumnow. Excellent summary slide by Dr. Elena Nikiphorou with 10 great take-home messages to share with your patient on diet and rheumatic disease. https://t.co/N7mq73KzLF
Eric Dein ejdein1 ( View Tweet)
EULAR Best Abstracts - Day 2 #EULAR2021
https://t.co/X0WZgpclRC https://t.co/f3pFNhoMIR
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Which patients with psoriasis are at risk to develop PsA?
The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.
https://t.co/5sj5HSnke3 https://t.co/NwoIoDH5rC
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we
Eric Dein ejdein1 ( View Tweet)
#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database
88.4% live births, 10.5% preg loss, 0.8% still birth
2.4% congen malform (w/2.1% major)
Preg loss⬅️Crohn's, NSAIDS, MTX
Preterm labor⬅️GCs, maternal infx
⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge
k dao KDAO2011 ( View Tweet)
JUNIPERA - secukinumab in enthesitis related arthritis and juvenile PsA
⭐️achieved JIA ACR response compared to placebo
⭐️⬇️time to flare
⭐️75% with resolution of enthesitis
⭐️0 deaths, AE - minor infections, GI issues, headache
Abs#LB0004
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
What's your ideal anti-rheumatic diet? #EULAR Pres6882 @Rheumnow @andreafava
Eric Dein ejdein1 ( View Tweet)
Real-world data from PsABio: 🚺generally start biologics in a worse PsA state than🚹. Although treatment improvements were similar between sexes, 🚺remained in worse health at 1 yr, and stopped/switched bDMARD earlier. Abstract #OP0232 #EULAR2021 @RheumNow https://t.co/oIGu0HzisQ https://t.co/uLnYOq8ypx
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Looking for RA specific coverage? We've got you covered. #EULAR2021
https://t.co/eXD5UK2RRp https://t.co/RI3aMW2E2g
Links:
Dr. John Cush RheumNow ( View Tweet)
SPIRIT-P1&P2: IXE is effective in⬇️axial symptoms & improving QoL in active PsA pts with axial involvement. Abstract #POS1045 #EULAR2021 @RheumNow https://t.co/GC78Lmp9cH https://t.co/WfaUqIRrY6
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
A single dose of LORECIVIVINT IA (Wnt pathway modulator) in Phase 3 study in knee OA: mild improvement of WOMAC pain -8.16[-15.60, -0.71] P=0.032 and function -9.47[-17.09, -1.84] P=0.015 at 6 and 12months with no particular safety signal. #POS0278 #EULAR2021 @RheumNow https://t.co/5qQE6MPjnU
Aurelie Najm AurelieRheumo ( View Tweet)
#POS1069 Quite promising results of the use of an easy to use quick quantitative CRP assay to be included in the DAPSA to facilitate immediate decision making. @ProftDr
In 98% identical disease activity classification than with #DAPSA
#EULAR2021 @RheumNow https://t.co/Rt8fKvKBC4
Paul Studenic Stiddyo ( View Tweet)
Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 )
https://t.co/z8c8moIQCa
#EULAR2021
Links:
Dr. John Cush RheumNow ( View Tweet)
PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal.
#LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI
Aurelie Najm AurelieRheumo ( View Tweet)
We need to look after #mentalhealth (MH) of #SLE patients.Dr Petri studied large US database. MH prevalence = 36%(SLE) and 29%(Nephritis;LN).LN with MH stayed 7.2 days longer in-patient vs without MH. Health cost/year⬆️in SLE+MH ($49,553 vs $26,064) #EULAR2021 #POS0304 @RheumNow https://t.co/wa7XmJxx9O
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)